Business Context and Reporting Period
This Form 8-K was filed by Charles River Laboratories International, Inc. on January 13, 2026. The filing serves as a current report regarding the company's upcoming presentation at the J.P. Morgan 44th Annual Healthcare Conference. It details preliminary operational trends for the fourth quarter of 2025, provides a financial outlook for 2026, and announces two strategic acquisitions.
Key Financial Metrics and Operational Data
The filing contains preliminary estimates and forward-looking guidance rather than finalized audited financial statements for the period.
- Q4 2025 DSA Net Book-to-Bill: Preliminary estimate of approximately 1.1x, driven by improved demand trends in the second half of 2025.
- 2026 Revenue Outlook: Management expects the top end of the organic revenue growth rate guidance range to be at least flat for both consolidated and Discovery and Safety Assessment (DSA) segments.
- 2026 Non-GAAP Operating Margin: Expected to benefit from incremental cost savings totaling over $100 million to offset inflation.
- Foreign Exchange (FX): Expected to provide an incremental benefit of 100-150 basis points to reported revenue growth in 2026.
Material Changes and Strategic Developments
The filing highlights two significant acquisitions expected to close in the first quarter of 2026:
- Acquisition of K.F. (Cambodia) Ltd.:
- Purpose: Vertical integration of non-human primate (NHP) supply for the DSA segment.
- Price: Approximately $510 million.
- Financial Impact: Not expected to generate meaningful third-party revenue. Expected to be accretive to non-GAAP earnings per share by approximately $0.25 in 2026 and $0.60 in 2027.
- Acquisition of PathoQuest SAS:
- Purpose: Expansion of next-generation sequencing (NGS) solutions for the Manufacturing Solutions segment.
- Price: Approximately €51.6 million (approx. $60 million) for the remaining 79% equity stake.
- Financial Impact: Expected to generate $15 to $20 million in annual revenue in 2026. Not expected to have a material impact on 2026 or 2027 GAAP or non-GAAP results.
Guidance, Outlook, and Risks
Management expressed cautious optimism regarding the return to revenue growth in the second half of 2026, driven by favorable DSA demand KPIs. However, they noted specific headwinds:
- Manufacturing Segment: Expected improvement in organic revenue growth may be offset by headwinds in the Research Models and Services (RMS) segment due to the timing of NHP shipments and CRADL occupancy.
- Acquisition Risks: The filing includes standard "safe harbor" language regarding the uncertainty of closing the proposed acquisitions, integration challenges, and the potential for actual results to differ materially from forward-looking statements.
- Non-GAAP Measures: The company notes that a reconciliation to GAAP measures for the acquisition accretion is not provided due to the uncertainty of future events and integration costs.
Investor Verification Checklist
- Verify the final closing dates and purchase price adjustments for the K.F. (Cambodia) Ltd. and PathoQuest SAS acquisitions.
- Monitor the actual Q4 2025 audited financial results to confirm the preliminary 1.1x DSA net book-to-bill estimate.
- Track the realization of the projected >$100 million in cost savings against actual inflation rates in 2026.
- Assess the impact of RMS headwinds (NHP shipments and CRADL occupancy) on the Manufacturing segment's ability to offset growth.
- Review the integration progress of K.F. (Cambodia) Ltd. to ensure the projected EPS accretion is achieved.